Corbus Pharmaceuticals Holdings (CRBP) Current Deferred Revenue (2015 - 2020)

Corbus Pharmaceuticals Holdings' Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $270530.0 for Q2 2020.

• In Q2 2020, Current Deferred Revenue fell 89.1% year-over-year to $270530.0; the TTM figure through Jun 2020 stood at $270530.0 (down 89.1% YoY), while the FY2018 annual figure was $35996.0, changed N/A from the prior year.
• Current Deferred Revenue was $270530.0 for Q2 2020 at Corbus Pharmaceuticals Holdings, down from $2.5 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $27.0 million in Q1 2019 to a low of $10263.0 in Q4 2016.
• Historically, Current Deferred Revenue has averaged $3.5 million across 5 years, with a median of $1.2 million in 2016.
• The sharpest annual moves came in 2016 and 2018: Current Deferred Revenue plunged 99.36% in 2016, then soared 1412.16% in 2018.
• A 5-year view of Current Deferred Revenue shows it stood at $10263.0 in 2016, then soared by 2787.18% to $296311.0 in 2017, then tumbled by 87.85% to $35996.0 in 2018, then soared by 6795.87% to $2.5 million in 2019, then plunged by 89.1% to $270530.0 in 2020.
• The last three Current Deferred Revenue figures came in at $270530.0 (Q2 2020), $2.5 million (Q2 2019), and $27.0 million (Q1 2019), per Business Quant data.